Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year periodKush M. Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures, to continue as a member of the Vor Board of DirectorsTania Philipp promoted to Vor’s Chief People Officer from Vice President and Head of People CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combination with targeted therapies for the treatment of cancer, today announced Matthew R. Patterson as Chairman of its Board of Directors. Mr. Patterson, who joined Vor’s Board as a member in October 2020, brings nearly 30 years of senior leadership experience in the research, development and commercialization of innovative therapeutics, most recently at Audentes Therapeutics, Inc., which he co-fou
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Bio to Participate in Upcoming Investor ConferencesGlobeNewswire
- Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Vor Biopharma Inc. (NYSE: VOR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $12.00 price target on the stock.MarketBeat
- Vor Biopharma Inc. (NYSE: VOR) had its price target lowered by analysts at Stifel Nicolaus from $15.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock, down previously from $17.00.MarketBeat
VOR
Earnings
- 11/7/23 - Miss
VOR
Sec Filings
- 4/9/24 - Form ARS
- 4/9/24 - Form DEFA14A
- 4/9/24 - Form DEF
- VOR's page on the SEC website